124I Positron Emission Tomography Versus 131I Planar Imaging in the Identification of Residual Thyroid Tissue and/or Metastasis in Patients Who Have Well-Differentiated Thyroid Cancer

被引:60
|
作者
Van Nostrand, Douglas [1 ]
Moreau, Shari [1 ]
Bandaru, Varalakshmi V. [1 ]
Atkins, Frank [1 ]
Chennupati, Shyam [1 ]
Mete, Mihriye [2 ]
Burman, Kenneth [3 ]
Wartofsky, Leonard [4 ]
机构
[1] Washington Hosp Ctr, Div Nucl Med, Washington, DC 20010 USA
[2] MedStar Res Inst, Dept Biostat & Epidemiol, Washington, DC USA
[3] Washington Hosp Ctr, Div Endocrinol, Washington, DC 20010 USA
[4] Washington Hosp Ctr, Dept Med, Washington, DC 20010 USA
关键词
DOSIMETRY; CARCINOMA; PET; THERAPY; IMPACT; CT;
D O I
10.1089/thy.2009.0430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective: I-124 emits a positron and can be imaged with a positron emission tomography (PET) scanner. The objective of this study was to compare the ability of diagnostic 124 I PET images versus I-131 planar whole-body imaging in detecting residual thyroid tissue and/or metastatic well-differentiated thyroid cancer (WDTC). Methods: Patients were recruited prospectively for this study who (i) had WDTC, (ii) were suspected of having metastatic WDTC, and (iii) were referred for I-131 whole-body dosimetry. The prescribed activity was 1-2 mCi (37-74 MBq) and 1.7 mCi (62.9MBq) for I-131 and I-124, respectively. For each image, one blinded reader (D.V.N.) categorized every focus of I-131 and I-124 radioiodine uptake as 1 definite physiological uptake/artifact, 2 most likely physiological uptake/artifact, 3 indeterminate, 4 residual thyroid tissue/metastases in the neck/ bed, 5 most likely metastases, or 6 definite metastases. Foci categorized as 4, 5, or 6 were considered positive. When available, foci categorized as 4, 5, or 6 were correlated with other diagnostic studies. Results: Of the 25 patients, 8 patients (32%) had more positive foci on I-124 images than on I-131, of which 3 patients to date have had metastases confirmed in one or more of the additional positive I-124 foci. I-124 demonstrated the same number of foci as on I-131 in 16 patients (14 with no positive foci, and 2 with two positive and five positive foci each). One patient had one additional positive focus on I-131 not seen on I-124, which has not yet been confirmed as a metastasis. A total of 97 positive foci were identified on either I-124 or I-131. I-124 identified 49 positive foci not seen with I-131, and I-131 identified one positive focus not seen with I-124. Conclusion: Relative to I-131 planar whole-body imaging, I-124 PET identified as many as 50% more foci of radioiodine uptake suggestive of additional residual thyroid tissue and/or metastases in as many as 32% more patients who had WDTC.
引用
收藏
页码:879 / 883
页数:5
相关论文
共 40 条
  • [1] 124I Positron Emission Tomography/Computed Tomography Versus Conventional Radioiodine Imaging in Differentiated Thyroid Cancer: A Review
    Wu, Di
    Ylli, Dorina
    Heimlich, S. Layla
    Burman, Kenneth D.
    Wartofsky, Leonard
    Van Nostrand, Douglas
    THYROID, 2019, 29 (11) : 1523 - 1535
  • [2] Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in the Identification of Metastasis in Differentiated Thyroid Cancer with 131I Planar Whole-Body Imaging and 124I PET
    Van Nostrand, Douglas
    Khorjekar, Gauri R.
    O'Neil, Jeff
    Moreau, Shari
    Atkins, Frank B.
    Kharazi, Pejman
    Mete, Mihriye
    Chennupati, Shyam P.
    Burman, Kenneth D.
    Wartofsky, Leonard
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (03) : 359 - 362
  • [3] Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer
    Van Nostrand, D.
    ORAL DISEASES, 2011, 17 (02) : 154 - 161
  • [4] Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
    Plyku, Donika
    Hobbs, Robert F.
    Huang, Kevin
    Atkins, Frank
    Garcia, Carlos
    Sgouros, George
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (07) : 1146 - 1154
  • [5] Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I
    Pettinato, C.
    Monari, F.
    Nanni, C.
    Allegri, V.
    Marcatili, S.
    Civollani, S.
    Cima, S.
    Spezi, E.
    Mazzarotto, R.
    Fanti, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 56 (06): : 509 - 514
  • [6] 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET)
    Kist, Jakob W.
    de Keizer, Bart
    van der Vlies, Manfred
    Brouwers, Adrienne H.
    Huysmans, Dyde A.
    van der Zant, Friso M.
    Hermsen, Rick
    Stokkel, Marcel P. M.
    Hoekstra, Otto S.
    Vogel, Wouter V.
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (05) : 701 - 707
  • [7] To Ablate or Not to Ablate: Issues and Evidence Involved in 131I Ablation of Residual Thyroid Tissue in Patients with Differentiated Thyroid Carcinoma
    Goldsmith, Stanley J.
    SEMINARS IN NUCLEAR MEDICINE, 2011, 41 (02) : 96 - 104
  • [8] The comparison of 131I whole-body scans on the third and tenth day after 131I therapy in patients with well-differentiated thyroid cancer: preliminary report
    Lee, Jeong Won
    Lee, Sang Mi
    Koh, Gwan Pyo
    Lee, Dae Ho
    ANNALS OF NUCLEAR MEDICINE, 2011, 25 (06) : 439 - 446
  • [9] Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports
    Tien-Shang Huang
    P. U. Chieng
    C. C. Chang
    R. F. Yen
    Journal of Endocrinological Investigation, 1998, 21 : 392 - 398
  • [10] Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning
    Pettinato, Cinzia
    Spezi, Emiliano
    Nanni, Cristina
    Grassetto, Gaia
    Monari, Fabio
    Allegri, Vincenzo
    Civollani, Simona
    Cima, Simona
    Zagni, Paolo
    Mazzarotto, Renzo
    Colletti, Patrick M.
    Rubello, Domenico
    Fanti, Stefano
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (08) : E367 - E374